fid 6 - 1 3 ^ 7 SRPT T-76fci MIN 315/022356 PERFLUOROOCTANESULFONYL FLUORIDE (POSF) T 'lk k l.3 /A V/T0 MAMMALIAN CHROMOSOME ABERRATION TEST IN HUMAN LYM PHOCYTES Sponsor 3M Center 3M Corporate Toxicology Building 220-2E-02 St Paul MN 55133-3220 USA Page 1 of 31 Research Laboratory Huntingdon Life Sciences Ltd Woolley Road Alconbury Huntingdon Cambridgeshire PE28 4HS ENGLAND Report issued 22 October 2002 001542 MIN 315/022356 CONTENTS Page CONTENTS.......................................................................................................................... 2 COMPLIANCE WITH GOOD LABORATORY PRACTICE STANDARDS..................... 4 QUALITY ASSURANCE STATEMENT............................................................................. 5 RESPONSIBLE PERSONNEL............................................................................................. 6 SUMMARY.......................................................................................................................... 1 INTRODUCTION.................................................................................................................. 8 TEST SUBSTANCE.............................................................................................................. 10 EXPERIMENTAL PROCEDURE......................................................................................... 11 ASSESSMENT OF RESULTS.............................................................................................. 15 MAINTENANCE OF RECORDS......................................................................................... 15 RESULTS.............................................................................................................................. 16 CONCLUSION...................................................................................................................... 17 REFERENCES....................................................................................................................... 18 :2: 001543 MIN 315/022356 COMPLIANCE WITH GOOD LABORATORY PRACTICE STANDARDS The study described in this report was conducted in compliance with the following Good Laboratory Practice standards, with the exceptions stated below, and I consider the data generated to be valid.

Katherine E .

/\@-3,3yts f 3 ( p PFOS: A REPRODUCTION STUDY WITH THE MALLARD FINAL REPORT WILDLIFE INTERNATIONAL, LTD.

AR226-2100 ?

Robert F Pinchot 07/09/2001 07:26 AM To: Catherine A Barton/AE/DuPont@ DuPont cc: Debbie J Mulrooney/AE/DuPont DuPont Subject: Re: ||) Cathie, Debbie, Sorry, I forgot to send that to you.

AR226-2212 C hris JE S hoop 11/07/2001 04:47 PM To: Debbie J Mulrooney/AE/DuPont@DuPont, Karl G Kronberg/AE/DuPont@DuPont cc: Subject: Data Sheet for Permitted Emissions CONFIDENTIAL COMMUNICATION Debbie, Here is the sheet I promised but I will need to have Kari complete the cells for FEP, and check the cells for PFA.

AR226-2230 Robert F Pinchot 12/11/2001 08:34 AM To: Debbie J Mulrooney/AE/DuPont@DuPont co: Chris E Shoop/AE/DuPont@DuPont, David M Rurak/AE/DuPont@DuPont Subject DRAFT for 815D Stack Diameter Change Requestoop Debbie, Please take a look at this.

AR226-2256 Chris E Shoop 02/18/2002 12:30 PM____________________________ _____ To: Debbie J Mulrooney/AE/DuPont@DuPont cc: Robert I Wevodau/SE/DuPont@DuPont, Robert F Pinchot/DEV/AE/DuPont@DuPont Subject: Re: Case 10 Questions O Debbie, The production rates in Case 10 were from forecasts for about 2007.

AR226-2277 Robert I Wevodau 05/21/2002 09:36 AM To: George L Clowes_Jr/CL/DuPont@DuPont, Ravinder Singh/CL/DuPont@DuPont, Michael T Evans/AE,'DuPont@DuPont, Michael G McClusky/AE/DuPont@DuPont, Cynthia E Read/AE/DuPont@DuPont, Ta-Wei Fu/SE/DuPont@DuPont cc: Stephen J Gissy/AE/DuPont@DuPont, Chris E Shoop/AE/DuPont@DuPont, Karl G Kronberg/AE/DuPont@DuPont Subject: C8 Modeling W e are anticipating th at TERA will soon release an annual exposure level for C8.

Stephen W C onstable 09/08/2000 11:02 AM To: W illiam G 0 'Brien/AE/DuPont@DuPont cc: Ta-Wei Fu/CL/DuPont@DuPont Subject: analytical for C8 I met willi Ta-Wei (his morning and he mentioned dial you were searching for a method to analyze CK.

AR226-2486 David M Rurak 09/06/2002 01:11 PM To: Robert F Pinchot/DEV/AE/DuPont@DuPont cc: Subject: Environmental coordination -- Forw arded by David M R urak/AE/DuPont on 0 9/0 6/20 0 2 01:10 PM - f Uma Chowdhry ' 0 8 /28 /2 0 0 2 11:16 AM To: David M Rurak/AE/DuPont@DuPont cc: Subject: Environmental coordination I hear you are the env coordinator for the C8 issue.,!

P-1 AR226-3586 January 30, 2006 70Q ~O lo-l^5l DuPont Corporate Remediation Group Barley Mill Plaza - Bldg. 19 4417 Lancaster Pike Wilmington, DE 19805 GS FE3 - ' ;.

Katherine E.

P-1 COMPANY SANITIZED - Does not contain TSCA Confidential Business Information (CBI) DAUUN AZza _ 3730 fi o>2 <> DAIKIN AMERICA, INC. 905 State Docks Road (35601) P.O.

ATSttCn:A SDeocctuiomne8n(et)P/FroYcIessing Center Attachment 1 P-1 P-1 July 28,2006 Page 4 of 5 M Z26 _373J- Acronym codefor Tables 1 and 2 In Tables 1 and 2, the following acronyms are used: acronym meaning CW FW WW DuPont Chambers Works facility in Deepwater, New Jersey DuPont Fayetteville Works facility in Fayetteville, North Carolina DuPont Washington Works facility in Parkersburg, West Virginia PPPFFFHPBeAxAA PFHpA PPPPFFFFOUDNnAAAA PFDoA PFBS PPPFFFOHOSxSSA PPeerrfflluuoorroobpuentatannooicicaacicdid Perfluorohexanoic acid Perfluoroheptanoic acid Perfluorooctanoic acid Perfluorononanoic acid Perfluorodecanoic acid Perfluorotmdecanoic acid PPPeeerrrfffllluuuooorrrooobhdueoxtdaaennceaenssuoulilfcfooanncaaitdtee Perfluorooctane sulfonate Perfluorooctane sulfonamide Attachment 1 Spaed Matrix Lab Blank 1 cw # P % cw p 3 cw n m 34 CW (DUPLICATE) c w v 5 cw i cw < P * CW 7 cw qp ( CW WG18817-102 Y2 WG18817-101 Y1 L8789-1 Y1 LB789-2 Y1 L87B9-3 Y1 WG18817-103Y1 L8789-4 Y1 L8789-5 Y1 LB789-5 Y1 LB789-6 Y1 L8789-7 Y1 L8789-8 Y1 % Recovery ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL WQ18817 W Q 18817 WQ18817 WQ18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 PFBA 81.2 ND ND ND ND ND ND <1.44 <1.44 <1.44 NO ND PFPeA 79.0 ND ND ND ND ND ND ND NO ND ND ND PFHxA 85.8 ND 1.82 ND <0.900 <0.900 ND ND ND <0.900 ND <0.900 PFHpA 83.5 ND ND ND ND ND <1.41 3.71 3.71 11.7 6.91 ND PFO A 110 ND 7.71 9.72 24.1 21.6 42.8 13.4 13.4 111 56.7 26.6 PFNA 11B ND 4.28 2.90 7.10 6.78 18.3 4.22 4.22 53.1 29.2 2.37 PFDA 115 ND <1.06 <1.08 1.64 1.51 8.47 1.82 1.82 13.5 7.47 <1.08 PFUnA 128 ND <1.02 <1.02 2.37 2.60 1.70 <1.02 <1.02 3.99 1.55 ND PFDoA 60.9 ND ND ND <0.600 <0 600 0.943 <0.600 <0.600 1.10 0.737 ND PFBS 94.8 ND ND ND ND ND ND ND ND ND ND ND PFHxS 104 ND <3.72 <3.72 39.1 33.5 <3.72 <3.72 <3.72 4.28 <3.72 3.81 PFOS 112 ND 51.1 35.3 68.2 58.0 25.7 35.0 36.0 39.0 53.8 36.8 PFO SA 73.5 ND ND ND ND ND ND ND ND NO ND ND Attachment 1 PFBA PFPeA PFHxA PFHpA PFOA PFNA PFDA PFUnA PFDoA PFBS PFHxS PFOS PFOSA tp // CW ^ k F w t f f lV L8789-9 Y1 LS789-10Y1 L8789-11 Y1 ngftnL ngAnL WG1B817 WG18817 ngAmL WG18817 ND ND NO ND ND ND ND ND ND NO 1.48 ND 12.9 13.0 28.3 <1.53 3.97 2.28 ND <1.08 <1.08 ND <1.02 <1.02 ND ND ND ND ND ND <3.72 <3.72 6.64 30.7 46.9 37.2 ND ND ND t-2.